Frequently Asked Questions about Exelixis, Inc. (EXEL)

Name: Exelixis, Inc. (EXEL) Institutional Financial Dataset
Creator: Olyth
License: https://olyth.xyz

Question 1

What does Exelixis, Inc. (EXEL) do?

Accepted Answer

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who receiv...

Question 2

Is Exelixis, Inc. (EXEL) a good stock to buy?

Accepted Answer

Olyth's institutional analysis of EXEL reveals an Altman Z-Score of 12.62 and a Piotroski F-Score of 6/9. These metrics, combined with its 5-year revenue trend ($2.32B most recent), help investors decide if EXEL fits their risk profile.

Question 3

What is the current P/E ratio for EXEL?

Accepted Answer

As of the latest trading session, Exelixis, Inc. (EXEL) has a trailing P/E ratio of 15.28.

Question 4

Who is the CEO of Exelixis, Inc.?

Accepted Answer

The current Chief Executive Officer of Exelixis, Inc. is Michael Morrissey.

Question 5

What was EXEL's revenue for the last 5 years?

Accepted Answer

According to its latest income statements, Exelixis, Inc. reported annual revenues of $2.32B (2026), $2.17B (2025), $1.83B (2023), $1.61B (2022), $1.43B (2021) respectively.

Question 6

Does EXEL pay a dividend?

Accepted Answer

Exelixis, Inc. does not currently pay a dividend to its shareholders.

Question 7

How much debt and cash flow does EXEL have?

Accepted Answer

In its latest reporting period, Exelixis, Inc. generated $0.84B in Free Cash Flow against a total debt load of $0.17B.

Question 8

What is the Price-to-Book (P/B) ratio of Exelixis, Inc.?

Accepted Answer

The Price-to-Book (P/B) ratio for Exelixis, Inc. (EXEL) is currently 5.53.

Question 9

What is the Price-to-Sales (P/S) ratio of EXEL?

Accepted Answer

Based on trailing twelve-month data, Exelixis, Inc. (EXEL) trades at a Price-to-Sales (P/S) ratio of 5.09.

Question 10

What is Exelixis, Inc.'s Return on Equity (ROE)?

Accepted Answer

Exelixis, Inc. (EXEL) has a Return on Equity (ROE) of 36.89%, representing its profitability relative to shareholder equity.

Period	Operating CF	SBC	CapEx	Free CF	True FCF
2026-01	884.3M	113M	-39.9M	844.3M	731.4M
2025-01	700M	93.8M	-66.2M	633.8M	540M
2023-12	333.3M	106.3M	-163M	170.4M	64M
2022-12	362.6M	107.6M	-138.5M	224.2M	116.6M
2021-12	400.8M	119.8M	-64.2M	336.6M	216.8M

Period	Operating CF	SBC	CapEx	Free CF	True FCF
2026-01	884.3M	113M	-39.9M	844.3M	731.4M
2025-01	700M	93.8M	-66.2M	633.8M	540M
2023-12	333.3M	106.3M	-163M	170.4M	64M
2022-12	362.6M	107.6M	-138.5M	224.2M	116.6M
2021-12	400.8M	119.8M	-64.2M	336.6M	216.8M